Panel Paper:
Explaining the Rise in Spending for High-Price Drugs in Medicare Part D
*Names in bold indicate Presenter
This study seeks to determine if rebates are indeed lower for high-price drugs than other drugs, especially for those drugs used most heavily by the Medicare population. I develop a drug-year-level measure of drug rebates by comparing the annual U.S. invoice spending on drugs with the net U.S. revenues reported by drug manufacturers in filings with the Securities and Exchange Commission filings and other publicly available data. Controlling for observable covariates, I regress this rebate percentage on an interaction between an indicator variable for a drug being a high-price drug (per user per month spending > $1,000) and the drug’s Medicare market share (i.e., the percent of users of the drug that are Medicare beneficiaries). The results of this study will help inform recent policy proposals put forth by the U.S. Secretary of Health and Human Services related to changing the cost-sharing structure of catastrophic coverage in Medicare Part D. It will also have important implications if, as proposed, many physician-administered specialty drugs are moved to Part D coverage.